

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 February 2025 (27.02.2025)



(10) International Publication Number
WO 2025/043036 A3

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/712 (2006.01)
A61K 31/519 (2006.01) A61K 31/713 (2006.01)
A61K 31/7064 (2006.01) A61K 47/54 (2017.01)
A61K 31/7115 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/043317

(22) International Filing Date:

22 August 2024 (22.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/578,033 22 August 2023 (22.08.2023) US

(71) Applicant: **THE RESEARCH FOUNDATION FOR
THE STATE UNIVERSITY OF NEW YORK** [US/US];
35 State Street, Albany, New York 12207 (US).

(72) Inventors: **JU, Jingfang**; 85 John Adams Lane, East Se-
tauket, New York 11733 (US). **OJIMA, Iwao**; 41 Roslyn
Court, Port Jefferson, New York 11777 (US). **YUEN,
John**; 12 Emily Drive, Centereach, New York 11720 (US).
CHEN, Lei; 1 Rock Island Road, Centereach, New York
11720 (US).

(74) Agent: **GROLZ, Edward**; Scully, Scott, Murphy & Press-
er, 400 Garden City Plaza, Suite 300, Garden City, New
York 11530 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

27 March 2025 (27.03.2025)



WO 2025/043036 A3

(54) Title: 5-HALOURACIL-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS AND THEIR USE IN THE TREATMENT OF CANCER

(57) Abstract: The present disclosure provides double-stranded nucleic acid compositions that incorporate uracil, gemcitabine, and methotrexate (MTX). More specifically, the present disclosure reveals that the modifications of double-stranded micro-RNA nucleotide sequences with 5-fluorouracil, gemcitabine and methotrexate (MTX) enhance the therapeutic efficacy of tumor suppression and tumor specificity. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-fluorouracil, gemcitabine and methotrexate (MTX) incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions (e.g., formulations) comprising the modified nucleic acid compositions, and methods for treating cancers, such as pancreatic cancer. This is a platform technology that can be applied to other tumor suppressor miRNAs as well as siRNAs.